Rehmann Capital Advisory Group Lowers Position in Stryker Corporation $SYK

Rehmann Capital Advisory Group trimmed its holdings in shares of Stryker Corporation (NYSE:SYK) by 5.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 60,357 shares of the medical technology company’s stock after selling 3,191 shares during the quarter. Stryker comprises about 0.8% of Rehmann Capital Advisory Group’s holdings, making the stock its 22nd largest position. Rehmann Capital Advisory Group’s holdings in Stryker were worth $19,003,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Brighton Jones LLC raised its position in shares of Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after buying an additional 609 shares in the last quarter. Schnieders Capital Management LLC. bought a new position in Stryker in the second quarter valued at $205,000. Marshall Wace LLP increased its stake in Stryker by 107.9% in the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after acquiring an additional 77,831 shares during the last quarter. Nebula Research & Development LLC purchased a new stake in Stryker during the second quarter valued at about $219,000. Finally, HUB Investment Partners LLC bought a new stake in Stryker during the second quarter worth about $253,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Down 1.9%

Shares of Stryker stock opened at $324.32 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86. The company’s 50 day moving average price is $329.49 and its 200-day moving average price is $331.03. The stock has a market capitalization of $124.40 billion, a price-to-earnings ratio of 33.61, a P/E/G ratio of 2.11 and a beta of 0.76.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same quarter in the prior year, the company posted $3.13 EPS. The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts forecast that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is 36.48%.

Analyst Ratings Changes

SYK has been the topic of several recent research reports. Royal Bank Of Canada reduced their price objective on Stryker from $435.00 to $420.00 and set an “outperform” rating on the stock in a research report on Friday, July 31st. Barclays reduced their price target on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research report on Monday, May 4th. Citigroup restated a “buy” rating on shares of Stryker in a report on Thursday, August 13th. Wolfe Research cut shares of Stryker from an “outperform” rating to a “peer perform” rating in a research note on Thursday, August 13th. Finally, Leerink Partners decreased their target price on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research report on Friday, June 5th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

Insider Activity

In related news, insider Debra King sold 826 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider owned 6,210 shares in the company, valued at $2,088,423. This represents a 11.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 300,000 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the sale, the director directly owned 2,301,375 shares of the company’s stock, valued at $773,031,862.50. The trade was a 11.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 351,267 shares of company stock valued at $118,197,701. Company insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.